High BAFF expression associated with active disease in systemic lupus erythematosus and relationship with rs9514828C>T polymorphism in TNFSF13B gene
- PMID: 30747361
- DOI: 10.1007/s10238-019-00549-8
High BAFF expression associated with active disease in systemic lupus erythematosus and relationship with rs9514828C>T polymorphism in TNFSF13B gene
Abstract
B cell-activating factor (BAFF) promotes the survival, proliferation and maturation of B lymphocytes, which are key elements in the pathogenesis of systemic lupus erythematosus (SLE). This cytokine is encoded on TNFSF13B gene, and diverse single-nucleotide polymorphisms have been associated with susceptibility in different autoimmune disorders. In this study, the relationship of TNFSF13B gene rs9514827T>C, rs1041567T>A and rs9514828C>T polymorphisms, mRNA expression and soluble BAFF levels was investigated in 175 SLE patients and 208 healthy controls (HC). The TNFSF13B polymorphisms were evaluated by PCR-RFLP technique. The TNFSF13B gene expression was quantified through the RT-PCR assays. The soluble BAFF (sBAFF) levels were measured with ELISA test. There were no differences in genotype and allele frequencies for the three TNFSF13B polymorphisms, between SLE patients and HC. SLE patients showed 3.15-fold more TNFSF13B gene expression than HC. The patients who displayed most mRNA expression were those with active disease and the carriers of rs9514828 T variant allele. The sBAFF serum levels were higher in SLE patients compared to HC (2.083 vs. 0.742 ng/mL, p < 0.001). The SLE patients with active disease showed the higher sBAFF serum levels (2.403 ng/mL), mainly patients with lupus nephritis and hematological manifestations. In addition, a correlation of sBAFF with disease activity was found (r = 0.32, p < 0.001). In conclusion, the TNFSF13B gene polymorphisms were not found to be associated with SLE susceptibility in Mexican mestizos. Nevertheless, rs9514828C>T polymorphism seems to increase TNFSF13B gene expression. High BAFF expression is related to active disease, renal and hematological involvement; therefore, it could be considered as follow-up biomarker in SLE patients.
Keywords: BAFF; Disease activity; Systemic lupus erythematosus; TNFSF13B polymorphisms.
Similar articles
-
Associations between TNFSF13B polymorphisms and primary Sjögren's syndrome susceptibility in primary Sjögren's syndrome patients: A meta-analysis.Immun Inflamm Dis. 2023 Dec;11(12):e1103. doi: 10.1002/iid3.1103. Immun Inflamm Dis. 2023. PMID: 38156381 Free PMC article. Review.
-
Analysis of TNFSF13B polymorphisms and BAFF expression in rheumatoid arthritis and primary Sjögren's syndrome patients.Mol Genet Genomic Med. 2022 Jun;10(6):e1950. doi: 10.1002/mgg3.1950. Epub 2022 Apr 12. Mol Genet Genomic Med. 2022. PMID: 35411715 Free PMC article.
-
TNFSF13B rs9514828 gene polymorphism and soluble B cell activating factor levels: Association with apical periodontitis.Int Endod J. 2023 Apr;56(4):419-431. doi: 10.1111/iej.13879. Epub 2022 Dec 30. Int Endod J. 2023. PMID: 36508294
-
Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis.BMC Nephrol. 2019 Nov 21;20(1):430. doi: 10.1186/s12882-019-1623-4. BMC Nephrol. 2019. PMID: 31752784 Free PMC article.
-
Cellular and molecular heterogeneity in systemic lupus erythematosus.Semin Immunol. 2021 Dec;58:101653. doi: 10.1016/j.smim.2022.101653. Epub 2022 Sep 29. Semin Immunol. 2021. PMID: 36184357 Review. No abstract available.
Cited by
-
TNFSF13B rs9514828 C>T Polymorphism is Associated with Incidence of Atherosclerosis and Therapeutic Outcomes in Patients with Systemic Lupus Erythematosus.Biologics. 2024 May 3;18:95-106. doi: 10.2147/BTT.S452792. eCollection 2024. Biologics. 2024. PMID: 38715569 Free PMC article.
-
Associations between TNFSF13B polymorphisms and primary Sjögren's syndrome susceptibility in primary Sjögren's syndrome patients: A meta-analysis.Immun Inflamm Dis. 2023 Dec;11(12):e1103. doi: 10.1002/iid3.1103. Immun Inflamm Dis. 2023. PMID: 38156381 Free PMC article. Review.
-
Association between levels of serum and urinary B cell-activating factor and systemic lupus erythematosus disease activity.Arch Rheumatol. 2023 Jun 14;38(3):429-440. doi: 10.46497/ArchRheumatol.2023.9549. eCollection 2023 Sep. Arch Rheumatol. 2023. PMID: 38046245 Free PMC article.
-
Induced Overexpression of B Cell-Activating Factor by Triiodothyronine Results in Abnormal B Cell Differentiation in Mice.Cell Transplant. 2023 Jan-Dec;32:9636897231204075. doi: 10.1177/09636897231204075. Cell Transplant. 2023. PMID: 37798940 Free PMC article.
-
Activation of Toll-like receptor 4 by thyroid hormone triggers abnormal B-cell activation.Immun Inflamm Dis. 2023 Sep;11(9):e1007. doi: 10.1002/iid3.1007. Immun Inflamm Dis. 2023. PMID: 37773690 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical